Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 12,030
-180 (-1.47%)
At close: Jan 16, 2026
Prestige BioPharma Company Description
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines in Singapore.
The company’s approved product is Trastuzumab Biosimilar for treatment the of early breast cancer, metastatic breast cancer, and metastatic gastric cancer.
In addition, its pipeline includes Adalimumab, which is in phase 1 trial for arthritis; and Bevacizumab, in phase 3 clinical study for non-small cell lung cancer, colorectal cancer.
It is also developing diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.
Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Prestige BioPharma Limited
| Country | Singapore |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | So-Yeon Park |
Contact Details
Address: 21 Biopolis Road Singapore, 138567 Singapore | |
| Phone | 65 6924 6535 |
| Website | prestigebiopharma.com |
Stock Details
| Ticker Symbol | 950210 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | KRW |
| ISIN Number | KR8702070002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| So-Yeon Park | Chairman and Chief Executive Officer |
| Jinwoo Kim | Chief Financial Officer and Director |
| Chung Shii Hii | Chief Technology Officer |
| Dong -Jo Shin | Head of Finance |
| Michael Ruppert | Head of Business Development |
| Wei Hsiung Lee | Secretary |
| Kay K.H. Lee | Clinical Development Manager |
| Ghislain M.C Bonamy | General Manager of Licensing |